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Secreted semaphorin 5A suppressed pancreatic tumour burden
but increased metastasis and endothelial cell proliferation
A Sadanandam*,1,2,3, SS Sidhu4, S Wullschleger3, S Singh1, ML Varney1, C-S Yang1, AE Ashour5, SK Batra6
and RK Singh*,1,6
1Department of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198-5900, USA;
2Swiss Institute of Bioinformatics (SIB), Quartier Sorge, Batiment Genopode, Lausanne 1015, Switzerland; 3Swiss Institute for Experimental Cancer
Research (ISREC), Swiss Federal Institute of Lausanne (EPFL), Station 19, Batiment SV, Lausanne 1015, Switzerland; 4Institut National de la Santé et de
la Recherche Médicale U753, Laboratoire Immunologie des Tumeurs Humaines, Interaction Effecteurs Cytotoxiques-Système Tumoral, Institut Fédératif
de Recherche-54, Villejuif, France; 5Department of Pharmacology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; 6Department
of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA
BACKGROUND: Our earlier reports demonstrated that membrane-bound semaphorin 5A (SEMA5A) is expressed in aggressive
pancreatic cancer cells and tumours, and promotes tumour growth and metastasis. In this study, we examine whether (1) pancreatic
cancer cells secrete SEMA5A and (2) that secreted SEMA5A modulates certain phenotypes associated with tumour progression,
angiogenesis and metastasis through various other molecular factors and signalling proteins.
METHODS AND RESULTS: In this study, we show that human pancreatic cancer cell lines secrete the extracellular domain (ECD) of
SEMA5A (SEMA5A-ECD) and overexpression of mouse Sema5A-ECD in Panc1 cells (not expressing SEMA5A; Panc1-Sema5A-
ECD; control cells - Panc1-control) significantly increases their invasion in vitro via enhanced ERK phosphorylation. Interestingly,
orthotopic injection of Panc1-Sema5A-ECD cells into athymic nude mice results in a lower primary tumour burden, but enhances the
micrometastases to the liver as compared with Panc1-control cells. Furthermore, there is a significant increase in proliferation of
endothelial cells treated with conditioned media (CM) from Panc1-Sema5A-ECD cells and a significant increase in microvessel density
in Panc1-Sema5A-ECD orthotopic tumours compared with those from Panc1-control cells, suggesting that the increase in liver
micrometastases is probably due to increased tumour angiogenesis. In addition, our data demonstrate that this increase in endothelial
cell proliferation by Sema5A-ECD is mediated through the angiogenic molecules – interleukin-8 and vascular endothelial growth
factor.
CONCLUSION: Taken together, these results suggest that a bioactive, secreted form of Sema5A-ECD has an intriguing and potentially
important role in its ability to enhance pancreatic tumour invasiveness, angiogenesis and micrometastases.
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Pancreatic adenocarcinoma is one of the leading causes of cancer-
related deaths in the United States. The prognosis of patients
suffering from pancreatic adenocarcinoma is extremely poor. More
than 80% of patients suffer from metastatic disease at the time of
diagnosis and almost all the patients die either because of the local
disease or metastases. The overall survival of pancreatic cancer
patients is o6 months from the time of diagnosis and current
therapeutic strategies are inadequate (Stathis and Moore, 2010).
This low survival of pancreatic cancer patients is due to lack of
early detection and/or metastatic markers. This urges for a better
understanding of the molecular mechanism(s) behind pancreatic
adenocarcinoma tumour progression and metastasis to identify
novel metastatic markers for the disease.
Semaphorins are a family (containing eight subfamilies) of
axonal growth molecules that contain secreted, glycosylphospati-
dylinositol-anchored and transmembrane signalling proteins. They
share a conserved B500 amino acids semaphorin domain in their
N-terminal regions and have subfamily-specific domains in their
carboxy-terminal regions (Chen et al, 1998; Yazdani and Terman,
2006). They were originally identified as bi-functional axonal
growth molecules involved in the development of the nervous
system (Chen et al, 1998). Semaphorins exert their cellular
functions by binding to two different families of proteins called
plexins and neuropilins (Kolodkin et al, 1993; Chen et al, 1998;
Yazdani and Terman, 2006; Roth et al, 2009). In addition to their
function during normal physiological processes such as the
development of the nervous, cardiac, skeletal and vascular systems
as well as the immune response, semaphorins also have major
roles during pathogenesis of tumour formation, angiogenesis and
metastasis (Chen et al, 1998; Christensen et al, 1998; Brambilla
et al, 2000; Tamagnone and Comoglio, 2000; Kusy et al, 2005; Roth
et al, 2009; Sadanandam et al, 2010b). Among the different
semaphorins, the role of membrane-bound semaphorins in cancer
has recently drawn more attention.
Previously, we identified semaphorin 5A (SEMA5A), a trans-
membrane bound semaphorin, as a putative metastatic marker
for pancreatic cancer (Sadanandam et al, 2007). Semaphorin 5A is
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characterised by five thrombospondin-1-specific repeats in its
extracellular domain (ECD) in addition to the semaphorin and
plexin domains (Adams et al, 1996). Semaphorin 5A is known to
induce inhibitory responses during optic nerve development
(Oster et al, 2003) and also has major roles in innate immunity
(Sugimoto et al, 2006) and idiopathic autism (Melin et al, 2006).
For the first time, we observed the expression of SEMA5A in
human pancreatic tumours, but not in normal pancreatic tissue. In
addition, we showed that SEMA5A is expressed by pancreatic
cancer cell lines established from metastases, but not those from
primary tumours. We also demonstrated the membrane localisa-
tion of SEMA5A particularly to regions of cell–cell adhesion in
aggressive pancreatic cancer cell lines. Overexpression of mem-
brane-bound mouse Sema5A in pancreatic cancer cells has been
demonstrated to increase migration and aggregation in vitro and
tumorigenesis and metastasis in vivo (Sadanandam et al, 2010b).
These results suggest that membrane-bound SEMA5A functions as
a paracrine molecule involved in pancreatic tumour growth and
metastasis. However, different reports on various cancer types
either endogenously expressing SEMA5A or treated with the ECD
of mouse Sema5A have contrasting tumour phenotypes (Li and
Lee, 2010; Lu et al, 2010; Pan et al, 2010).
Recently, others and we have demonstrated the interaction of
Sema5A with Plexin B3 in different mouse tissues and various cell
lines (ectopically expressing Plexin B3; Artigiani et al, 2004;
Sadanandam et al, 2008). Moreover, we have demonstrated that
Sema5A is a proangiogenic molecule that regulates various steps of
angiogenesis including endothelial cell proliferation, survival and
migration in vitro and sprouting of blood vessels in vivo through
its functional receptor, Plexin B3 (Sadanandam et al, 2010a).
However, SEMA4D, a membrane-bound protein and a close
relative with structural similarity to SEMA5A (Sadanandam et al,
2007), has been shown to be secreted (Wang et al, 2001) and can
regulate tumour angiogenesis and metastasis (Basile et al, 2006).
In this report, we demonstrate that pancreatic cancer cells secrete
ECD of SEMA5A (SEMA5A-ECD) and that secreted Sema5A
enhances invasiveness and metastasis of tumour cells via ERK
phosphorylation and proliferation of endothelial cells through
upregulation of angiogenic factors.
MATERIALS AND METHODS
Cell culture
Human pancreatic cancer cell lines (Panc1 and T3M4) and
immortalised human dermal microvascular endothelial cells (HMEC-1;
obtained from the Centre for Disease Control and Prevention,
Atlanta, GA, USA; Ades et al, 1992) were maintained in culture as an
adherent monolayer with RPMI-1640/DMEM with 5% Foetal Calf
Serum (Mediatech, Herndon, VA, USA) supplemented with 1X
nonessential amino acids, 2mM L-glutamine and 1X vitamin solution.
Transfection of pancreatic cancer cells and purification of
recombinant protein
Panc1 cells were stably transfected with either 1mg of a cDNA
construct containing the mouse Sema5A-ECD conjugated to human
IgG Fcg cloned in to the pcDNA3.1 vector (generous gift from
Dr David Stretavan, University of California San Francisco at
San Francisco, CA, USA) or pcDNA3.1 control vector (Stratagene,
La Jolla, CA, USA) using LipofectAMINE (Invitrogen, Carlsbad, CA,
USA) according to the protocol provided by the manufacturer. Panc1
cells transfected with Sema5A-ECD (Panc1-Sema5A-ECD) or control
vector (Panc1-control) were selected and maintained with
400mgmlÿ 1 G418 sulphate (Mediatech). Fc-tagged Sema5A-ECD
was isolated by protein-A affinity chromatography from the super-
natant of Panc1-Sema5A-ECD expressing cells and the protein purity
was tested using silver staining (Fischer Chemical, Fairlawn, NJ, USA)
as described previously (Sadanandam et al, 2010a).
Tumorigenic and metastatic assays
The tumorigenic and metatstatic assays were performed using male
athymic BALB/c nude mice (NCI-nu, 6–8 weeks old, purchased from
the National Cancer Institute). In accordance with approval from the
American Association of Laboratory Animal Care and current
regulations and standards of the US Department of Agriculture,
Department of Health and Human Services and National Institute of
Health, the mice used for this study were maintained under specific
pathogen-free conditions in facilities. All procedures performed in
mice were in accordance with the institutional guidelines and were
approved by the University of Nebraska Medical Center Institution
Animal Care and Use Committee.
For tumour growth and metastasis, the preparation of cells
and the orthotopic injections in to the pancreas of the mice
were performed as described in our previous study (Sadanandam
et al, 2010b).
Immunohistochemistry (IHC)
Fixed paraffin-embedded tissue samples on slides were deparafi-
nised in a series of xylene and alcohol treatments (two times
xylenes, one time each in 100%, 95%, 80% and 70% alcohol) for
5min each. The slides were washed with PBS for 5min for three
times and quenched for endogenous peroxidase activity by
incubating with 3% H2O2 in PBS for 5min. Slides were again
washed thoroughly with PBS and blocked with blocking buffer
(10% horse/donkey serum) for 30min. Without further washing, the
samples were incubated with primary antibody (anti-PCNA
(5mgmlÿ 1, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-
SEMA5A (5mgmlÿ 1; Sadanandam et al, 2010b), anti-interleukin (IL)-
8 (2mgmlÿ 1), anti-vascular endothelial growth factor (VEGF;
2mgmlÿ 1; R&D System, Minneapolis, MN, USA) or
anti-CD31 (1 : 100, Abcam, Cambridge, MA, USA) in blocking buffer
for overnight at 41C and then with biotinylated secondary antibody
for 30min to 1h after washing with PBS. After washing the slides in
PBS, the samples were incubated with ABC reagent (Vector
Laboratories, Burlingame, CA, USA) for 15–30min. Finally, DAB
substrate (Vector Laboratories) was added until a brown colour
developed and counter stained with hematoxylin. The quantitation of
the number of cells stained for a particular antibody was determined
by counting at least five different random fields in the same section at
 200 resolution using a Nikon microscope (Nikon Inc., Melville,
NY, USA). The average number of positive cells was calculated.
mRNA analysis
Total cellular RNA isolation and reverse transcription based
polymerase chain reaction (RT–PCR) specific to SEMA5A and
b-actin was performed as described (Sadanandam et al, 2010b).
In vitro proliferation assay
For endothelial cell proliferation, cells (1 103) were seeded in
individual wells of 96-well flat-bottomed plates in triplicate and
treated with serum-free supernatant from Panc1-Sema5A-ECD or
Panc1-control cells. The proliferative activity of the cells after 72h of
incubation was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay using a microtiter plate
reader (Bio-Tek Instruments, Inc., Winooski, VT, USA) at 570nm as
described (Sadanandam et al, 2010a).
Invasion and migration assay
For invasion assay, cells (1 105) were plated onto the upper
chamber of transwell chambers and coated with matrigel (6.5mm;
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Corning Costar Corp., Cambridge, MA, USA) on the bottom of the
upper chamber. MTT was added to the wells during the last 2 h of
incubation. Using a cotton swab, the residual cells from the top of
the transwell chambers were removed. The inserts were transferred
to a carrier plate and dimethyl sulfoxide was added to solubilise
the crystals. The migratory activity was measured by reading at
570 nm using a microplate reader.
For migration assay using MEK1 inhibitor (PD98059, Millipore,
Billerica, MA, USA), cells (1 105) along with 10 mM MEK1
inhibitor or media alone were plated onto the upper chamber of
transwell chambers and media on the bottom chamber. The cells
were incubated for 4 h at 371C and cells that did not pass through
the membrane pores were removed using a cotton swab. Migrated
cells were stained using the Hema 3 kit (Fisher Scientific Company
L.L.C., Kalamazoo, MI, USA) as per the manufacturer’s instruc-
tions. Cells were counted in 10 random fields ( 200) and
expressed as the average number of cells per field of view. The data
are represented as the average of three independent experiments.
Immunoprecipitation and western blot analysis
Cells (1 106) were plated on 10-cm cell culture dishes and serum-
starved for 24 h. Serum-free supernatants or conditioned media
(CM) and lysates from T3M4 cells were collected, concentrated
using Amicon Ultra-30 Centrifugal Filter Units (Millipore) and
were directly subjected to western blot as described (Sadanandam
et al, 2010b).
For immunoprecipiation, CM from Panc1-Sema5A-ECD or
control cells were collected and were immunoprecipitated using
Protein A/G (Invitrogen) and anti-SEMA5A antibody and incu-
bated at 4 1C overnight. Later, the immunoprecipitates were
washed three times using RIPA buffer followed by SDS–PAGE
and western blot using anti-SEMA5A antibody as described
(Sadanandam et al, 2008).
For ERK phosphorylation, pancreatic cancer cells were seeded in
10-cm cell culture dishes. After the cells reached 80–90%
confluence, cells were treated with Sema5A-ECD recombinant
protein (10 ngmlÿ 1) for 5 or 30min or media alone. Cells were
washed three times with cold PBS and lysed in membrane
lysis buffer and the lysates (20 mg perlane) were separated on
SDS–PAGE and subjected to western blot as described
(Sadanandam et al, 2010b). Densitometric quantitation of intensity
of the bands was performed using the ImageQuant (GE Healthcare,
Piscataway, NJ, USA).
Enzyme-linked immunosorbant assay (ELISA)
IL-8 or VEGF protein levels in culture supernatants were
determined using enzyme-linked immunosorbent assay (ELISA)
matched-pair antibodies for IL-8 (Endogen Inc., Woburn, MA,
USA) or VEGF (R&D Systems) according to the manufacturer’s
instructions with modification as described previously (Varney
et al, 2003). Briefly, 50 ml of culture supernatant from treated or
untreated cells was assayed in duplicate using the sandwich ELISA
technique. A standard curve of the absorbance vs the concentra-
tion of protein (IL-8 or VEGF) in the standard wells was generated.
We determined the concentration of protein in the unknown
samples by comparing the absorbance of the sample to the
standard curve.
Statistical analysis
The significance of the data was determined by the Student’s t-test
(two-tailed) for all the studies. Po0.05 was deemed significant. All
statistical analyses were done using the SPSS software (SPSS, Inc.,
Chicago, IL, USA).
RESULTS
Secretion of SEMA5A in pancreatic cancer cells
To examine whether pancreatic cancer cells secrete SEMA5A, we
performed western blots for SEMA5A using serum-free supernatant
(CM, see Materials and Methods for supernatant preparation) and
protein lysates collected from T3M4, a pancreatic cancer cell line
expressing high levels of SEMA5A (Sadanandam et al, 2010b). The
results shown in Figure 1A demonstrate a band at B110kD in the
T3M4 CM whereas the protein lysate shows bands at B135 kD
(membrane-bound SEMA5A) and B110 kD (equivalent to the
molecular weight of its extraceullar domain). These results suggest
that SEMA5A is secreted in pancreatic adenocarcinoma cell lines.
Overexpression of Sema5A-ECD in pancreatic cancer cells
increases their invasive potential
As the B110-kD band in T3M4 supernatant (Figure 1A) is
predicted to be equivalent to SEMA5A-ECD, we studied the role of
SEMA5A-ECD in pancreatic cancer. We stably transfected Panc1
cells, which do not express SEMA5A, with a cDNA construct
containing mouse Sema5A-ECD (Panc1-Sema5A-ECD) fused with
human IgG Fcg region at the C-terminus or with empty vector
(Panc1-control). Panc1-Sema5A-ECD cells expressed Sema5A
mRNA whereas Panc1-control cells did not show detectable levels
of Sema5A mRNA (Figure 1Ba). In addition, we performed
immunoprecipitation followed by western blot both using anti-
SEMA5A antibody and supernatant from Panc1-Sema5A-ECD and
Panc1-control. We observed a band between B180 and B220 kD
that represents the Sema5A-ECD plus with human IgG Fcg region
(Figure 1Bb) similar to that shown by Oster et al (2003).
Next, we examined whether expression of Sema5A-ECD
in pancreatic cancer cells modulates their invasive potential.
Significantly more Panc1-Sema5A-ECD cells invaded through
Matrigel as compared with control cells (Po0.05) in the absence
of serum (Figure 1C). This result demonstrates that Sema5A-ECD
modulates the invasive potential of pancreatic cancer cells.
Expression and phosphorylation of ERK in Sema5A treated
Panc1 cells
Downregulation of D-Sema5c has been shown to decrease phospho-
rylation of ERK in a Drosophila model for metastasis (Woodhouse
et al, 2003). To identify a signalling network mediating migration of
pancreatic cancer cells by secreted SEMA5A, we examined ERK
phosphorylation after treatment with recombinant Sema5A-ECD.
Increased levels of p42 ERK phosphorylation were observed in Panc1
cells treated with 10ngmlÿ 1 of Sema5A-ECD for 5 and 30min
compared with cells treated with media alone (Figures 1D and E) as
well as a slight increase in the level of p44 ERK phosphorylation
(Figure 1D and Supplementary Figure 1A). To verify if ERK
signalling is important for SEMA5A-ECD induced migration of
pancreatic cancer cells, we performed transwell chamber migration
assays by treating Panc1-Sema5A-ECD and Panc1-control cells with
10mM concentration of MEK1 inhibitor (PD98059) or media alone.
A significant decrease in migration of Panc1-Sema5A-ECD cells
with MEK1 inhibitor was observed compared with the treatment
with media alone whereas there was not much change in the Panc1-
control cells (Figure 1F). This data supports the hypothesis that
Sema5A-dependent cellular migration is mediated through the
increased ERK phosphorylation.
Sema5A-ECD overexpression enhances spontaneous
metastasis
To examine the role of Sema5A-ECD in tumour cells in
an orthotopic pancreatic microenvironment, we injected
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Panc1-Sema5A-ECD or Panc1-control (5 105) cells into the
pancreas of athymic nude mice. Mice were killed after 10 weeks.
The presence of primary tumour in the pancreas and metastatic
cells in different organs was confirmed by H&E staining (data
not shown). Surprisingly, no difference in tumour incidence
was observed between mice injected with Panc1-Sema5A-ECD or
Panc1-control cells (Figure 2A). However, in mice injected
with Panc1-Sema5A-ECD cells, tumour burden was lower and yet
there was an increased incidence of micrometastases to the
liver (Figure 2A). Though there were no obvious macrometastases
in either Panc1-Sema5A-ECD mice or control mice, there
was a significant increase in number of micrometastatic cells to
the liver (Figure 2B). To examine the proliferation of orthotopic
tumours, we examined PCNA staining in Panc1-Sema5A-ECD
and control tumours by IHC analysis using an anti-PCNA
antibody and then counting the number of positive cells. No
significant difference in PCNA staining was observed between
Panc1-Sema5A-ECD and control tumours (Supplementary
Figure 1B).
Next, we performed IHC for CD31 marker for microvessels
in orthotopic tumours. Here, we identified a significant increase in
microvessel density in orthotopic tumours expressing Sema5A-
ECD as compared with control tumours (Figures 2C and D). These
data suggest that Sema5A-ECD stimulates aggressiveness in
pancreatic tumour cells leading to increased micrometastases via
increased tumour angiogenesis, but with lower primary tumour
burden.
Sema5A-ECD increases endothelial cell proliferation
and upregulates expression of pro-angiogenic factors
To investigate whether Sema5A-ECD mediates increased metas-
tasis by increasing endothelial cell proliferation (one of the steps
involved in tumour angiogenesis), we performed MTT prolifera-
tion assays after treating HMEC-1 endothelial cells with condi-
tioned serum-free supernatants from Panc1-Sema5A-ECD or
Panc1-control cells (Figure 3A). Significantly increased prolifera-
tion was observed in HMEC-1 cells treated with serum-free
conditioned supernatant from Panc1-Sema5A-ECD as compared
with that from Panc1-control cells (Figure 3A). This result
demonstrates that Sema5A-ECD increases proliferation of
endothelial cells.
Next, we examined the expression of well-known pro-angiogenic
regulators IL-8 and VEGF in the serum-free supernatants of Panc1-
Sema5A-ECD or control cells in vitro by ELISA. Interleukin-8 and
VEGF were significantly increased in the supernatant of Panc1-
Sema5A-ECD cells as compared with control cells (Figures 3B
and C). We further validated the regulation of IL-8 and VEGF
expression by Sema5A-ECD by treating Panc1-Sema5A-ECD cells
with neutralising antibody to Sema5A for 72 h and then measuring
the expression levels of IL-8 and VEGF in the supernatant using
ELISA. A significant decrease (Po0.05) in IL-8 and VEGF protein
expression was seen in the supernatant of Panc1-Sema5A-ECD
treated with 10 ng of neutralising antibody to Sema5A (Figures 3D










































































































































Figure 1 Secretion of SEMA5A and its invasive role in pancreatic cancer cells. (A) A representative western blot analysis showing expression
of membrane-bound SEMA5A in protein lysates and secretion of SEMA5A in supernatant of human pancreatic cancer cell line – T3M4. (B) A standard
(a) RT–PCR (using specific primers) and (b) immunoprecipitation and western blot analysis (using anti-SEMA5A antibody) of Panc1 cells ectopically
expressing mouse Sema5A-ECD (Panc1-Sema5A-ECD) and control vector (Panc1-control) showing expression of Sema5A. b-Actin was used as an internal
control for RT–PCR. (C) Cellular invasion in Panc1-Sema5A-ECD or Panc1-control after 1 h was measured using Matrigel-coated transwell chambers and
MTT assay. Invasion was measured as mean optical density (OD) at 570 nm (OD570 nm)±standard deviation (s.d., bars) of triplicate culture and *a statistical
significance of Po0.05. (D) Western blot analysis of phosphorylated and total ERK in protein lysates of Panc1 cells treated with 10 ngmlÿ 1 of recombinant
Sema5A-ECD protein at different time points (5 or 30min) or media alone using appropriate antibodies. (E) Densitometric quantitation of phosphorylated
p44 ERK that was normalised to total p44 ERK from western blots from (D) using the ImageQuant software. (F) Cellular migration in Panc1-Sema5A and
Panc1-control after 4 h was measured after treating the cells either with 10 mM MEK1 inhibitor (PD98059) or media alone (control) using uncoated transwell
chambers and the number of migrated cells was counted at  10 magnification using a Nikon microscope. The values are number of migrated cells±s.d.
(bars) of triplicate culture and *a statistical significance of Po0.05 using Student t-test.
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Panc1-Sema5A-ECD orthotopic tumours as compared with control
tumours by IHC (Po0.05; Figures 3F and G). However, we did not
observe a significant change in VEGF staining between orthotopic
tumours from Panc1-Sema5A-ECD and Panc1-control
(Supplementary Figure 1C). These results demonstrate that
Sema5A-ECD increases the protein expression of IL-8 and to a
certain extent VEGF in pancreatic cancer cells and tumours.
DISCUSSION
Previously, we found that pancreatic tumours and aggressive
pancreatic cancer cell lines express membrane-bound SEMA5A,
however, it is not expressed in normal pancreatic tissues or less
aggressive pancreatic cancer cell lines (Sadanandam et al, 2007,
2010b). In this study, we sought to determine if pancreatic cancer
cells secrete SEMA5A and whether secreted SEMA5A has a role in
pancreatic tumour progression, metastasis and angiogenesis by
regulating other molecules.
Many secreted forms of membrane-associated proteins such as
CD44 (Stickeler et al, 2000) and transforming growth factor-b type
III receptor (Bandyopadhyay et al, 2002) were reported to be
involved in tumour metastasis. One transmembrane protein of the
semaphorin family, SEMA4D, which displays structural similarity
to SEMA5A (Sadanandam et al, 2007), has also been reported to be
released as a functional secreted protein and has been shown to be
involved in tumorigenesis and metastasis (Wang et al, 2001; Basile
et al, 2004, 2006). In this report, we detected SEMA5A protein in the
serum-free supernatant of a human pancreatic cancer cell line
(T3M4) and the B110-kD band was predicted to be similar to that
of the Sema5A-ECD. To our knowledge, this is the first report
showing that SEMA5A is secreted.
In our previous study, we demonstrated that membrane-bound
Sema5A increases pancreatic cancer invasion in vitro and
metastasis in vivo (Sadanandam et al, 2010b). In this report, we
studied the role of secreted SEMA5A in pancreatic tumour
progression and metastasis by overexpressing mouse Sema5A-
ECD in Panc1 cells not expressing SEMA5A. Sema5A-ECD
expression in pancreatic cancer cells demonstrated increased
invasion in vitro. This increase in invasion of pancreatic cancer
cells induced by Sema5A-ECD especially in serum-free conditions
suggests that this molecule is a motogenic factor secreted by
tumour cells.
Previously, we have shown that orthotopic injections of
pancreatic cancer cells overexpressing membrane-bound Sema5A
in athymic nude mice are tumorigenic and metastatic
(Sadanandam et al, 2010b). Here, we demonstrate that orthotopic
injection of Sema5A-ECD-expressing cells resulted in reduced
tumour burden, but enhanced micrometastases to the liver as
compared with control transfected cells. It has already been
reported that small primary tumours could lead to metastasis in
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of tumour in g
Primary tumour
Panc1-control 24.68 ± 3.34 100
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Figure 2 Orthotopic assay, micrometastasis and microvessel density of Panc-1 Sema5A-ECD. Athymic nude mice (n¼ 5) were injected orthotopically
with Panc1-control or Panc1-Sema5A-ECD and were euthanised after 10 weeks. (A) Average weight of mice and tumour (tumour burden) as well as
incidence of primary tumour and metastasis to the liver is shown. (B) There are a significantly enhanced number of micrometastatic cells per field of  200
resolution of the Nikon microscope in the liver in Panc-1-Sema5A-ECD tumour-bearing mice as compared to control mice. (C) Immunohistochemistry
using CD31 staining showing microvessels in Panc1-Sema5A-ECD and control orthotopic tumours. There is an increased angiogenesis in Panc1-Sema5A-
ECD compared to the Panc1-control orthotopic tumours. (D) Densitometric quantitation of microvessel density from C. per field at  200 resolution of
the Nikon microscope. The values are number of microvessels±s.d. (bars) of five different areas per field or different slides and *a statistical significance of
Po0.05.
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et al, 2008). The mechanism by which secreted Sema5A induces
increased metastasis with reduced tumour burden is intriguing.
Based on our previous findings that Panc1 cells express Plexin B3,
a functional receptor for SEMA5A (Sadanandam et al, 2008), we
suggest that the secretion of SEMA5A in pancreatic cancer induces
an autocrine mechanism via the ERK phosphorylation to
metastasise to distant organs but with smaller primary tumour,
unravelling this cell signalling mechanism might be the basis of
our future studies.
We have previously shown that Sema5A can promote angiogen-
esis, in general (Sadanandam et al, 2010a). In this study, we show
that Panc1-Sema5A-ECD is biologically active and also has the
ability to promote tumour angiogenesis as shown by its ability to
significantly increase in vitro proliferation of HMEC-1 endothelial
cells and significantly increase microvessel density in orthotopic
Panc1-Sema5A-ECD tumours compared with control tumours. In
addition, supernatants from Panc1-Sema5A-ECD cells show
increased expression of pro-angiogenic factors, IL-8 and VEGF.
We speculate that secreted Sema5A derived from the membrane-
bound protein could be the reason for the increased IL-8 and
VEGF expression. The direct effect of Sema5A-ECD on endothelial
cells to secrete IL-8 and VEGF was shown using neutralising
antibody against Sema5A in endothelial cells. Overall, the increase
in micrometastasis in Sema5A-ECD-expressing pancreatic cancer
cells is due to increased tumour angiogenesis via IL-8 and VEGF.
In conclusion, in this study, for the first time we show that
malignant pancreatic cancer cells secrete SEMA5A and that this
secreted form demonstrates the ability to drive micrometastatic
spread via the enhancement of angiogenesis and migration of
pancreatic cancer cells via increased ERK signalling and expression
of angiogenic factors, but with reduced primary tumour burden.
These results suggest a potentially important and hitherto
unsuspected role of the secreted form of SEMA5A in pancreatic
cancer metastasis. Further study is warranted to examine the
presence of secreted SEMA5A in pancreatic cancer patients and to




























































































































































































Figure 3 Sema5A-ECD stimulates endothelial cell proliferation and increases the expression of angiogenic factors. (A) MTT proliferation assay after 72 h
using 1000 HMEC-1 cells per well that were treated with conditioned medium (no serum) from Panc1-Sema5A-ECD or Panc1-control. There is a significant
(Po0.05) increase in proliferation of HMEC-1 in the presence of supernatant from Panc1-Sema5A-ECD cells compared with control cells with no serum.
Proliferation was measured as mean optical density (OD) at 570 nm (OD570 nm)±s.d. (bars) of triplicate culture and *statistical significance of Po0.05.
Enzyme-linked immunosorbent assay for (B) IL-8 and (C) VEGF protein in the supernatant of Panc1-Sema5A-ECD and Panc1-control cells using
appropriate antibodies. There is increased expression of IL-8 and VEGF in the supernatants of Panc1-Sema5A-ECD compared with control. Data are mean
pg mg-1±s.e.m. (bars) of triplicate samples and *statistical significance of Po0.05. Neutralisation of Sema5A-ECD in supernatants of Panc1-Sema5A-ECD
using 10 ngmlÿ 1 of anti-Sema5A or rabbit-IgG antibody followed by ELISA for (D) IL-8 or (E) VEGF. There is a significant decrease in IL-8 and VEGF using
10 ngmlÿ 1 of anti-Sema5A antibody compared with rabbit-IgG. Data are mean pg/OD±s.d. (bars) of triplicate samples and *statistical significance of
Po0.05. (F) Immunohistochemistry showing IL-8 staining in (a) Panc1-control and (b) Panc1-Sema5A-ECD orthotopic tumours using anti-IL-8 antibody.
The magnification is  200 resolution using a Nikon microscope. (G) The number of cells positive for IL-8 from F. The values are mean number of
cells±s.d. (bars) of three slides. *Statistical significant difference of Po0.05.
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